Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938117 | 0.83 | IDO1 (0.46) | IDO1SLC6A2SLC6A4HDAC3HDAC1 | |
| SCHEMBL5823897 | 0.83 | IDO1 (0.42) | IDO1SLC6A2SLC6A4HDAC3HDAC1 | |
| SCHEMBL1538597 | 0.83 | IDO1 (0.63) | IDO1SLC6A2SLC6A4HDAC3HDAC1 | |
| SCHEMBL3278241 | 0.81 | IDO1 (0.61) | IDO1SLC6A2SLC6A4HDAC3HDAC1 | |
| SCHEMBL109671 | 0.79 | IDO1 (0.65) | IDO1SLC6A2SLC6A4HDAC3HDAC1 | |
| SCHEMBL14647652 | 0.79 | IDO1 (0.59) | IDO1SLC6A2SLC6A4HDAC3HDAC1 | |
| SCHEMBL1873922 | 0.79 | DAO (0.46) | IDO1SLC6A4 | |
| SCHEMBL7804289 | 0.79 | POLQ (0.47) | IDO1SLC6A4P2RX7 | |
| SCHEMBL488748 | 0.79 | IDO1 (0.59) | IDO1SLC6A2SLC6A4HDAC3HDAC1 | |
| SCHEMBL8417818 | 0.79 | IDO1 (0.59) | IDO1SLC6A2SLC6A4HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3837263-B1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20210277020-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-09-09 | — | — | US | disclosed |
| US-20200308190-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-01 | — | — | US | disclosed |
| EP-3404017-B1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | NISSAN CHEMICAL IND LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| US-10336686-B2 | Fluorine atom-containing compound and use thereof | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20190031600-A1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2019-01-31 | — | — | US | disclosed |
| EP-3404017-A1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | Nissan Chemical Industries, Ltd. (JP) | 2018-11-21 | — | — | EP | disclosed |
| JP-2005200396-A | FLUORINE-CONTAINING BENZAL CHLORIDE AND METHOD FOR PRODUCING THE SAME | CENTRAL GLASS CO LTD | 2005-07-28 | — | — | JP | disclosed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | disclosed |
| WO-2005011655-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
| EP-1073655-B1 | PHARMACEUTICALLY AVAILABLE PROTOBERBERINE SALTS DERIVATIVES, AND PROTOBERBERINE DERIVATIVES AND SALTS THEREOF | HANWHA CHEMICAL CORP (KR) | 2004-04-14 | — | — | EP | disclosed |
| CN-1134436-C | Pharmaceutically available protoberberine salt derivatives, and protoberberine derivatives and salt thereof | — | 2004-01-14 | — | — | CN | disclosed |
| CN-1295573-A | Pharmaceutically available protoberberine salt derivatives, and protoberberine derivatives and salt thereof | HANWHA PETROCHEMICAL CO LTD (KR) | 2001-05-16 | — | — | CN | disclosed |
| EP-1073655-A1 | PHARMACEUTICALLY AVAILABLE PROTOBERBERINE SALTS DERIVATIVES, AND PROTOBERBERINE DERIVATIVES AND SALTS THEREOF | HANWHA CHEMICAL CORPORATION (KR) | 2001-02-07 | — | — | EP | disclosed |
| US-6030978-A | EXHIBIT FUNGICIDAL EFFECT OR GROWTH-INHIBITORY EFFECT AGAINST FUNGI INCLUDING CUTANEOUS FILAMENTOUS FUNGUS, SUCH AS EPIDERMOPHYTON, MICROSPORUM, TRICHOPHYTON, SPOROTHRIX SCHENCKII, ASPERGILLUS OR CANDIDA; NONTOXICITY; | HANWHA CORPORATION (KR) | 2000-02-29 | — | — | US | disclosed |
| US-6008356-A | BRBERINE SALT DERIVATIVE IS REACTED WITH SODIUM TETRABORATE AND POTASSIUM CARBONATE IN ALCOHOL SOLVEANT TO FORM INTERMEDIATE, REACTING INTERMEDIATE WITH ALKYL SUBSTITUENT IN ACETONITRILE SOLVENT, OXIDIZING THE FORMED INTERMEDIATE | HANWHA CORPORATION (KR) | 1999-12-28 | — | — | US | disclosed |
| WO-1999055704-A1 | PHARMACEUTICALLY AVAILABLE PROTOBERBERINE SALTS DERIVATIVES, AND PROTOBERBERINE DERIVATIVES AND SALTS THEREOF | HANWHA CHEMICAL CORPORATION (KR) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336686-B2 | Fluorine atom-containing compound and use thereof | ARF1, ARF5, ARFGAP1 | IDO1 2403/4885SLC6A2 1619/4885SLC6A4 1765/4885 |
| US-20210277020-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | IDO1 3585/4885SLC6A2 4793/4885SLC6A4 4860/4885 |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, SNRPD2 | IDO1 1844/4885SLC6A2 4000/4885SLC6A4 4274/4885 |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | IDO1 3378/4885SLC6A2 4730/4885SLC6A4 4796/4885 |
| US-20190031600-A1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | ARF1, ARF5, ARFGAP1 | IDO1 2403/4885SLC6A2 1619/4885SLC6A4 1765/4885 |
| US-20200308190-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, MGLL, LPL | IDO1 3714/4885SLC6A2 4690/4885SLC6A4 4776/4885 |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | IDO1 3378/4885SLC6A2 4730/4885SLC6A4 4796/4885 |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | IDO1 3378/4885SLC6A2 4730/4885SLC6A4 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.